Navigation Links
Osseon® Announces International Distribution Agreement with Aesculap
Date:2/27/2012

SANTA ROSA, Calif., Feb. 27, 2012 /PRNewswire/ -- Osseon® Therapeutics, Inc. announced today that the company has entered into an International Distribution Agreement with Aesculap AG to distribute its vertebral compression fracture (VCF) treatment devices, including its new CE-Mark approved device – Osseoflex® SB (steerable balloon) in select regions of Europe and Asia.  Aesculap is a division of B. Braun Melsungen, a large medical and pharmaceutical company headquartered in Tuttlingen, Germany.  The Osseoflex® SB and the other Osseon CE Mark approved VCF medical devices offer a complete platform for treatment of spinal fractures.

"Aesculap is a major medical device company known throughout the world as a quality manufacturer and distributor of surgical instruments.  Our new Osseoflex SB (steerable balloon) represents the most precise and controllable treatment device for vertebral compression fracture augmentation currently available to surgeons.  Osseon is very excited to partner with Aesculap to distribute our game-changing Osseoplasty® devices and procedures for VCF treatment to patients throughout Europe and the international community and provide state-of-the-art alternatives to the cumbersome devices and procedures currently used to treat fractures of the thoracic and lumbar spine," said John Stalcup, Ph.D., Osseon's CEO.

B. Braun is one of the world´s leading healthcare suppliers. Its four divisions orient their products and services toward different medical fields: hospital, surgery, private practice (medical care and doctors´ offices) and extracorporeal blood treatment.  Aesculap focuses on products and services for core processes in surgery.  Aesculap's product range includes surgical instruments for open or minimally invasive approaches, implants (e.g., for orthopaedics, neurosurgery and spinal surgery), surgical sutures, sterile container, storage, motor and navigation systems as well as products for cardiology.

About Osseon

Osseon® Therapeutics, Inc. focuses on bringing to market alternative minimally invasive treatments for degenerative bone and joint disease. Headquartered in Santa Rosa, CA, the company's innovative technology and delivery system provides comparable or better efficacy and safety than other commercial solutions, while offering significant advantages in efficiency and cost. By improving the treatment of compression fractures within the lower portion of the thoracic and the entire lumbar vertebral spine, Osseon offers alternative solutions to patients, as well as the physicians and medical facilities that treat them. Its products have received both FDA clearance and the CE Mark for product distribution in the United States and the European Union.

Osseon® is a registered trademark of Osseon Therapeutics, Inc.

For more information, visit our web site at www.osseon.com


'/>"/>
SOURCE Osseon Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Osseon® Therapeutics Introduces New Osseoflex® DR Steerable Bone Drill
2. Osseon® Therapeutics Names Gary Coughlen, CPA as New Chief Financial Officer
3. Osseon® Announces Commercial Release of Osseoflex®SN (Steerable Needle)
4. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
5. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
6. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
7. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
8. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
9. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
10. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
11. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/7/2017)... Pharmacy, Inc. (NYSE: DPLO), the nation,s largest independent specialty pharmacy, ...  All comparisons, unless otherwise noted, are to the quarter ended ... Second Quarter 2017 Highlights include: Revenue ... 3.5% Total prescriptions dispensed of 220,000, compared ... 7.6% Gross profit per prescription dispensed ...
(Date:8/2/2017)... , Aug. 2, 2017 ... Who,s Who as a Pinnacle Lifetime Professional in ... Key Account Manager at Turing Pharmaceuticals, AG. Her ... troubleshooting and relationship building.                ... more than 25 years of experience as a ...
(Date:7/31/2017)... 2017  Diplomat Pharmacy, Inc. (NYSE: DPLO), has been named ... by Crain,s Detroit Business . ... by three-year revenue growth. This year,s edition measures growth from ... view the complete list, visit crainsdetroit.com/awards/fast_50/2017 .  ... triumph," said Phil Hagerman , CEO and chairman of ...
Breaking Medicine Technology:
(Date:8/16/2017)... ... ... LabRoots , the leading provider of educational and interactive virtual events ... Andrew Ly as the winner of the LabRoots Summer Textbook scholarship, awarding him $1000 ... is in his third year at the University of California, Los Angeles majoring in ...
(Date:8/16/2017)... ... August 16, 2017 , ... ... the endoscope after every reprocessing cycle, both between patient procedures and before storage, ... infections. Drying is as important to the prevention of disease transmission and nosocomial ...
(Date:8/16/2017)... , ... August 16, 2017 , ... ... company based in Vero Beach, announced today that two of their associates were ... that represents professionally managed senior living communities in Florida. The awards were announced ...
(Date:8/16/2017)... ... , ... TopConsumerReviews.com recently gave a best-in-class 5 star rating to Test Country, ... the United States has undergone major changes over the last decade, particularly when it ... order to get a blood test or other lab work done. Today, most tests ...
(Date:8/16/2017)... ... August 16, 2017 , ... Women’s Excellence ... pelvic pain. In addition to oncology services, the new center will specialize ... (abnormal heavy bleeding during menstruation), uterine fibroids, and uterine and pelvic adhesions (scar ...
Breaking Medicine News(10 mins):